Claims
- 1. A method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula:
- 2. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof, of the formula:
- 3. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxycytidine or pharmaceutically acceptable salt or prodrug thereof of the formula:
- 4. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyuridine or pharmaceutically acceptable salt or prodrug thereof of the formula:
- 5. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyguanosine or pharmaceutically acceptable salt or prodrug thereof of the formula:
- 6. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyinosine or pharmaceutically acceptable salt or prodrug thereof of the formula:
- 7. The method of claim 1, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-thymidine or a pharmaceutically acceptable salt or prodrug thereof of the formula:
- 8. A method for treating a host infected with hepatitis B comprising administering an effective amount of two or more anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleosides or a pharmaceutically acceptable salt or prodrug thereof in combination or alternation, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleosides have the formula:
- 9. A method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof in combination or alternation with an additional anti-hepatitis B agent, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula:
- 10. The method of claim 9, wherein the additional anti-hepatitis B agent is selected from the group consisting of 3TC, FTC, L-FMAU, DAPD, famciclovir, penciclovir, BMS-200475, bis pom PMEA (adefovir, dipivoxil); lobucavir, ganciclovir, arid ribavarin
- 11. A compound or pharmaceutically acceptable salt or prodrug thereof of the formula:
- 12. A pharmaceutical composition comprising an effective amount of a compound of claim 11 in combination with a pharmaceutically acceptable carrier.
Parent Case Info
[0001] This application claims priority to U.S. provisional application U.S.S.No. 60/096,110, filed on Aug. 10, 1998 and U.S.S.No. 60/131,352, filed on Apr. 28, 1999.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60096110 |
Aug 1998 |
US |
|
60131352 |
Apr 1999 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
10022276 |
Dec 2001 |
US |
Child |
10438167 |
May 2003 |
US |
Parent |
09371747 |
Aug 1999 |
US |
Child |
10022276 |
Dec 2001 |
US |